← Leaderboards
Maryam Rahman
University Of Florida
$1,071,900
Attributed
$1,071,900
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $344K · FY2017–21$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,071,900 · 1
By mechanism
K08$1,071,900 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- Xingming Deng$11,809,682
- Elias Sayour$8,823,629
- Todd Michael Brusko$9,515,959
- Mauricio De Aguiar Martins$18,939,893
- John M Buatti$4,178,356
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseEfficacy TestingCytotoxic T-LymphocytesDna Sequence AlterationAntibodiesDrug UsageConditioningAftercareBrain NeoplasmsAdultCareerCareer DevelopmentCell KillingCellsAwardCessation Of LifeChemotherapyClinical InvestigationClinically SignificantClinical SciencesClinical TrialsCancer CenterCombinatorialEnvironment
Grant awards (7)
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma$181,980
K08 · FY2021 · NS · contact PI
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma$108,000
K08 · FY2021 · NS · contact PI
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma$54,000
K08 · FY2021 · NS · contact PI
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma$181,980
K08 · FY2020 · NS · contact PI
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma$181,980
K08 · FY2019 · NS · contact PI
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma$181,980
K08 · FY2018 · NS · contact PI
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma$181,980
K08 · FY2017 · NS · contact PI